Tag: clinical study

Aquestive's Subingual Epinephrine

Aquestive’s Sublingual Epinephrine Achieves Therapeutic Blood Concentrations Following Administration

Company presented top level Phase 1 results at #AAAAI2022 meeting.
Kids Being Vaccinated at VUMC

Vanderbilt Recruiting Children to Study Allergic Responses to COVID-19 mRNA Vaccines

Participating children will be closely monitored and observed by qualified staff at a children’s hospital.
Intranasal Delivery

Intranasal Delivery of Emergency Epinephrine Takes Another Step Toward Realization

Another company is reporting promising results in the race to bring an intranasal device to market.
Palforzia Capsules with Logo

Results of Aimmune’s Pivotal Phase 3 European Trial of PALFORZIA® Published...

Peanut-allergic patients treated with Palforzia showed desensitization to peanut protein with a predictable safety profile at nine months
Dupixent

FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...

Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
Intranasal Spray

Study: Intranasal Epinephrine Absorbed Faster Than Injection and Even Better with...

Study compared absorption of epinephrine via nasal spray to that of intramuscular injection.
Viaskin Peanut

DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...

Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
Peanuts

Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT

Continuing with a modest dose confers more protection, NIH-funded study finds.
Patient Undergoing SLIT

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...

UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
Baby

Recruitment of Infants Begins for Phase 3 Trial of Cream to...

The trial needs 760 babies aged three weeks or younger whose parents or siblings suffer from either eczema, asthma or food allergies.